ASML's Asian Relief Meets Washington's Regulatory Ambush

ASML gains from Middle East calm but faces a direct threat from the US MATCH Act, which could cut its crucial China sales. Investors await Q1 earnings and management's outlook.

A sudden easing of tensions in the Middle East provided a welcome boost for ASML this week, but the Dutch chip equipment giant now faces a more direct threat from Washington. As investors prepare for first-quarter earnings, a new bipartisan U.S. bill threatens to sever a critical revenue stream from China.

The announcement of a ceasefire involving Iran and the planned reopening of the Strait of Hormuz sent oil prices lower, offering significant relief to Asia's energy-import-dependent economies. This development is crucial for ASML, which typically derives 60 to 70 percent of its revenue from the Asian market. A sustained energy price shock would have dampened the investment appetite of key chipmakers in Taiwan, South Korea, and Japan. The stock, closing yesterday at 1,220.20 euros, has rallied over 23 percent since the start of the year, reflecting this geopolitical relief. It currently trades at 1,248.60 euros.

However, this positive momentum is being overshadowed by legislative efforts in the United States. The recently introduced "MATCH Act" takes aim directly at ASML's deep ultraviolet (DUV) lithography systems. If passed, the law would completely prohibit Chinese semiconductor giants like SMIC or Huawei from purchasing or receiving maintenance for these machines. China accounted for 33 percent of ASML's sales last year, making it the company's largest single market.

Analysts are scrambling to quantify the potential damage. Initial estimates suggest the new law could shave roughly five percent off total revenue, though this impact may diminish over time. JPMorgan analyst Sandeep Deshpande warns that earnings per share could be reduced by up to ten percent. While sales to other regions would likely increase, they are not expected to fully compensate for the loss of Chinese business. Unlike previous executive orders, this congressional initiative signals a broad political consensus in Washington, making it a more durable threat.

All eyes are now on Monday, April 15, when ASML reports its Q1 2026 results. Management has provided guidance expecting net sales between 8.2 and 8.9 billion euros and a gross margin of 51 to 53 percent. The core focus for investors will be management's commentary on order intake from China and any assessment of the MATCH Act's potential fallout. Their outlook will be key to confirming the ambitious full-year revenue forecast of up to 39 billion euros.

Beyond the earnings, ASML's shareholder calendar is packed. The annual general meeting on April 22 is set to feature proposed management contract renewations and a vote on a dividend of 2.70 euros per share, with payment scheduled for April 24. Meanwhile, the company continues to execute its share buyback program through 2028, acquiring around 125 million euros worth of stock weekly.

The upcoming earnings call provides the first major platform for ASML's leadership to address the regulatory risks head-on. Investors await a clear update on the annual forecast to gauge how Washington's latest move might reshape the company's operational landscape.